Evaluation of Circulating Tumor DNA in Patients with Ovarian Cancer Harboring Somatic PIK3CA or KRAS Mutations

• Published in: Cancer research and treatment Vol. 52; no. 4; pp. 1219 - 1228
• Main Authors: Ogasawara, Aiko, Hihara, Taro, Shintani, Daisuke, Yabuno, Akira, Ikeda, Yuji, Tai, Kenji, Fujiwara, Keiichi, Watanabe, Keisuke, Hasegawa, Kosei
• Format: Journal Article
• Language: English
• Published: Korea (South) Korean Cancer Association 01.10.2020; 대한암학회
• Subjects: Biomarkers, Tumor - blood; Biomarkers, Tumor - genetics; Carcinoma, Ovarian Epithelial - blood; Carcinoma, Ovarian Epithelial - genetics; Carcinoma, Ovarian Epithelial - mortality; Carcinoma, Ovarian Epithelial - therapy; Circulating Tumor DNA - blood; Circulating Tumor DNA - genetics; Class I Phosphatidylinositol 3-Kinases - genetics; Female; Humans; Liquid Biopsy - methods; Middle Aged; Mutation; Neoplasm Recurrence, Local - blood; Neoplasm Recurrence, Local - diagnosis; Neoplasm Recurrence, Local - epidemiology; Neoplasm Recurrence, Local - genetics; Original; Ovarian Neoplasms - blood; Ovarian Neoplasms - genetics; Ovarian Neoplasms - mortality; Ovarian Neoplasms - therapy; Preoperative Period; Prognosis; Progression-Free Survival; Proto-Oncogene Proteins p21(ras) - genetics; Risk Assessment - methods; 의학일반; Biomarker; KRAS; PIK3CA; Ovarian neoplasms; ctDNA
• ISSN: 1598-2998; 2005-9256
• DOI: 10.4143/crt.2019.688

Circulating tumor DNA (ctDNA) is an attractive source for liquid biopsy to understand molecular phenotypes of a tumor non-invasively, which is also expected to be both a diagnostic and prognostic marker. PIK3CA and KRAS are among the most frequently mutated genes in epithelial ovarian cancer (EOC). In addition, their hotspot mutations have already been identified and are ready for a highly sensitive analysis. Our aim is to clarify the significance of PIK3CA and KRAS mutations in the plasma of EOC patients as tumor-informed ctDNA. We screened 306 patients with ovarian tumors for somatic PIK3CA or KRAS mutations. A total of 85 EOC patients had somatic PIK3CA and/or KRAS mutations, and the corresponding mutations were subsequently analyzed using a droplet digital polymerase chain reaction in their plasma. The detection rates for ctDNA were 27% in EOC patients. Advanced stage and positive peritoneal cytology were associated with higher frequency of ctDNA detection. Preoperative ctDNA detection was found to be an indicator of outcomes, and multivariate analysis revealed that ctDNA remained an independent risk factor for recurrence (p=0.010). Moreover, we assessed the mutation frequency in matched plasma before surgery and at recurrence from 17 patients, and found six patients had higher mutation rates in cell-free DNA at recurrence compared to that at primary diagnosis. The presence of ctDNA at diagnosis was an indicator for recurrence, which suggests potential tumor spread even when tumors were localized at the time of diagnosis.